COVID-19 pandemic impacted a lot on how clinical trials and clinical research are being conducted. Medical professionals at medical sites are having difficulties to manage to start or continue clinical trials and clinical research. They will Identify problems at trial sites, pharmaceutical companies, and CROs and use them for future measures.
By holding DIA free and timely and workshop, we will enhance the value of DIA and lead to future DIA membership acquisition.
Topic: Impact of COVID-19 on Clinical Trials & Research: Identifying Problems at Trial Sites, Pharmaceutical Companies, and CROs
This program is conducted in Japanese Language only.
- Hironobu Saito, PhD, Corporate Officer, Head of Medical Affairs Div. Daiichi Sankyo Co., Ltd., Japan; Chair, DIA Advisory Council of Japan
Panel Discussion Co-Chairs:
- Eri Sekine, Department Head, Trial Monitoring, Japan Development, Global Development Ops., Novartis Pharma K.K., Japan
- Atsushi Tsukamoto PhD, Vice President, New Drug Regulatory Affairs,Daiichi Sankyo Company, Limited, Japan
- Hiroyuki Aono, Senior Advisor, Research and Development Solutions Center of Excellence, IQVIA Services Japan K.K., Japan
- Toshihiko Doi, MD, PhD, Deputy Director / Chief, Experimental Therapeutics, National Cancer Center Hospital East, Japan
- Yasutoshi Kuboki, MD, PhD, Experimental Therapeutics, National Cancer Center Hospital East, Japan
- Noriko Morishita, Manager, Clinical Trial Promotion Office, National Hospital Organization Headquarter, Japan
- Junko Sato, PhD, Director, Office of International Programs, Pharmaceuticals and Medical Devices Agency（PMDA）, Japan
- Naoto Uemura, MD, PhD, Professor, Faculty of Medicine Department of Clinical Pharmacology & Therapeutics, Oita university, Japan
- Noboru Yamamoto, MD, PhD, Deputy Director, Department of Experimental Therapeutics, National Cancer Center Hospital, Japan